<DOC>
	<DOCNO>NCT02789345</DOCNO>
	<brief_summary>The main purpose study evaluate safety ramucirumab necitumumab combination osimertinib participant non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Necitumumab ( LY3012211 ) Plus Osimertinib Participants With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have diagnosis NSCLC least 1 measurable lesion assessable use standard technique Response Evaluation Criteria Solid Tumors Version 1.1 ( RECIST 1.1 ) . Have T790Mpositive status use test validate perform locally disease progression EGFR tyrosine kinase inhibitor ( TKI ) treatment . Have Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 time enrollment . Have serum albumin ≥25 gram per liter time enrollment . Have adequate organ function , screen lab perform within 7 day treatment initiation . Have life expectancy ≥3 month . Have resolution , except otherwise state inclusion criterion , clinically significant toxic effect prior systemic cancer therapy , surgery , radiotherapy Grade ≤1 National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.0 . Previous treatment EGFR monoclonal antibody ( except past treatment squamous cell carcinoma head neck metastatic colorectal cancer ) . Previous treatment osimertinib third generation EGFR TKIs . Participants symptomatic grow brain metastasis less 4 week prior enrollment . History druginduced interstitial lung disease ( ILD ) , ILD , radiation pneumonitis require treatment steroid prior study enrollment , evidence clinically active ILD . Have significant bleeding disorder vasculitis Grade ≥3 bleed episode within 12 week prior enrollment . Participants history gross hemoptysis ( define bright red blood ≥1/2 teaspoon ) within 2 month prior enrollment exclude . Have experience arterial thrombotic event arterial thromboembolic event , include myocardial infarction , unstable angina ( history evidence current clinically relevant coronary artery disease current ≥Class III define Canadian Cardiovascular Society Angina Grading Scale congestive heart failure current ≥Class III define New York Heart Association ) , cerebrovascular accident , transient ischemic attack , within 6 month prior enrollment . Have history deep vein thrombosis , pulmonary embolism , significant venous thromboembolism ( venous catheter thrombosis superficial venous thrombosis consider `` significant '' ) 3 month prior study enrollment . Participants venous thromboembolism occur 3 6 month prior study enrollment allow , treat low molecular weight heparin . Have history gastrointestinal perforation and/or fistula within 6 month prior enrollment . Have bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection ( hemicolectomy extensive small intestine resection chronic diarrhea ) , Crohn 's disease , ulcerative colitis , chronic diarrhea . Have uncontrolled hypertension , define CTCAE Version 4.0 , prior initiate study treatment , despite antihypertensive intervention . CTCAE Version 4.0 defines uncontrolled hypertension Grade &gt; 2 hypertension ; clinically , participant continue experience elevate blood pressure ( systolic &gt; 160 millimeter mercury [ mmHg ] and/or diastolic &gt; 100 mmHg ) despite medication . Are receive chronic therapy follow medication within 7 day prior enrollment : nonsteroidal antiinflammatory agent ( NSAIDs ; indomethacin , ibuprofen , naproxen , similar agent ) . antiplatelet agent ( clopidogrel , ticlopidine , dipyridamole , anagrelide ) . Have radiologically document evidence major blood vessel invasion encasement cancer . Have radiographic evidence pulmonary intratumor cavitation , regardless tumor histology . Are receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , chemoembolization , target therapy radiotherapy treatment 30 % bone marrow wide field radiation within 4 week prior enrollment . Have abnormal cardiac finding . Have undergone chest irradiation within 2 week prior study drug administration , recover radiationrelated toxicity , require corticosteroid . A 2week washout permit focal palliative radiation noncentral nervous system disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>T790M</keyword>
	<keyword>epidermal growth factor receptor ( EGFR )</keyword>
</DOC>